COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age—Propensity Score-Matched Analysis of Austrian National Public Health Institute Data

Faisal Aziz 1, Felix Aberer 1, Alexander Bräuer 2, Christian Ciardi 3, Martin Clodi 4, Peter Fasching 2, Mario Karolyi 5, Alexandra Kautzky-Willer 6, Carmen Klammer 4, Oliver Malle 1, Erich Pawelka 5, Thomas Pieber 7, Slobodan Peric 8, Claudia Ress 8, Michael Schranz 10, Caren Sourij 11, Lars Stechemesser 10, Harald Stingl 12, Hannah Stöcher 1, Thomas Stulnig 9, Norbert Tripolt 1, Michael Wagner 12, Peter Wolf 6, Andreas Zitterl 5, Alexander Christian Reisinger 13, Jolanta Siller-Matula 14, Michael Hummer 15, Othmar Moser 16, Dirk von-Lewinski 11, Philipp Eller 13, Susanne Kaser 9, and Harald Sourij 1, 14 on behalf of the COVID-19 in Diabetes in Austria Study Group

Abstract: Background: It is a matter of debate whether diabetes alone or its associated comorbidities are responsible for severe COVID-19 outcomes. This study assessed the impact of diabetes on intensive care unit (ICU) admission and in-hospital mortality in hospitalized COVID-19 patients. Methods: A retrospective analysis was performed on a countrywide cohort of 40,632 COVID-19 patients hospitalized between March 2020 and March 2021. Data were provided by the Austrian data platform. The association of diabetes with outcomes was assessed using unmatched and propensity-score
matched (PSM) logistic regression. Results: 12.2% of patients had diabetes, 14.5% were admitted to the ICU, and 16.2% died in the hospital. Unmatched logistic regression analysis showed a significant association of diabetes (odds ratio [OR]: 1.24, 95% confidence interval [CI]: 1.15–1.34, \( p < 0.001 \)) with in-hospital mortality, whereas PSM analysis showed no significant association of diabetes with in-hospital mortality (OR: 1.08, 95%CI: 0.97–1.19, \( p = 0.146 \)). Diabetes was associated with higher odds of ICU admissions in both unmatched (OR: 1.36, 95%CI: 1.25–1.47, \( p < 0.001 \)) and PSM analysis (OR: 1.15, 95%CI: 1.04–1.28, \( p = 0.009 \)). Conclusions: People with diabetes were more likely to be admitted to ICU compared to those without diabetes. However, advanced age and comorbidities rather than diabetes itself were associated with increased in-hospital mortality in COVID-19 patients.

Keywords: COVID-19; diabetes; intensive care; mortality; SARS-CoV-2

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus that caused a pandemic of coronavirus disease starting in 2019 (COVID-19). As of 27 July 2021, 194.72 million confirmed cases of COVID-19 and 4.17 million deaths have been reported globally with an estimated fatality rate of approximately 2% [1,2].

Earlier research from China, the United States, and Europe has reported a high prevalence of diabetes (17–33%) among people hospitalized for COVID-19 [3–5]. In addition, people with diabetes are more likely to develop severe SARS-CoV-2 infection and complications such as diabetic ketoacidosis and death [2,6,7]. Various mechanisms have been delineated to understand the relationship between diabetes and COVID-19. As such, people with diabetes have a compromised immune system and dysfunctional inflammatory response, which may result in a more complex course of the disease and prolonged recovery. Moreover, SARS-CoV-2 infection may disrupt the regulation of blood glucose in people with diabetes, which provides a thriving environment to the virus, thereby making it challenging to treat this infection [8].

Recent studies have shown that certain risk factors such as old age, sex, and smoking status and the presence of comorbidities such as cardiovascular disease, dementia, liver disease, renal disease, and cancer also significantly increase the risk of developing severe disease and mortality in people with COVID-19 [5,7,9,10]. In particular, type 2 diabetes is a disease of advanced age with a high burden of multimorbidity [11]; it is speculated that the co-existence of these underlying conditions exacerbates the prognosis of COVID-19 in people with diabetes [12]. However, evidence concerning the impact of diabetes on COVID-19 outcomes that is independent of age, sex, and multimorbidity is still emerging [13,14]. Therefore, this study assessed the association of diabetes with the severity of disease leading to intensive care unit (ICU) admission and in-hospital mortality in patients hospitalized for SARS-CoV-2 infection in Austria by adopting a propensity score matching (PSM) method to account for sex, age, and comorbidities.

2. Materials and Methods

2.1. Study Design and Data Source

The ‘Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)’ checklist was used for reporting this study [15]. A retrospective cohort study was conducted in patients hospitalized for primary and secondary SARS-CoV-2 infection in Austria. These data were collected by the “Data platform COVID-19” provided by the Austrian National Public Health Institute (Gesundheit Österreich GmbH, Stubenring 6, 1010, Vienna, Austria).

This platform captures countrywide epidemiological and clinical data of COVID-19 patients in Austria to improve understanding and provide updated evidence regarding SARS-CoV-2 infection in the country. The details about the Austrian data platform are available at: https://datenplattform-covid.goeg.at/english, accessed on 3 May 2021.
2.2. Data Extraction and Study Variables

This study includes data of COVID-19 patients with and without diabetes mellitus who were hospitalized between March 2020 and March 2021 in Austria. Of the 51,469 patients recorded in the database, 40,602 patients were included in the final analysis after excluding patients aged below 20 years and with missing and duplicate data (Figure 1). Study variables comprised age deciles at admission, sex, number of hospitalizations for COVID-19, geographic regions, diabetes mellitus, comorbidities, ICU admission, and in-hospital mortality.

Data received from “Datenplattform COVID-19” (N = 51,469)

Excluded patients with missing ID number (n = 2851)

Excluded duplicate id numbers (n = 7089)

Excluded patients with age <20 years (n = 927)

Number of patients included in analysis (N = 40,602)

Figure 1. Flow diagram of extraction.

Diabetes mellitus was defined as per the International Classification of Disease (ICD) version 10 codes of E10, E11, E12, E13, and E14. Comorbidities were identified by referring to Charlson and Elixhauser indices and defined as per the ICD-10 codes. The comorbidities included myocardial infarction, cardiac arrhythmias, valvular heart disease, hypertension, congestive heart failure (CHF), peripheral vascular disease, stroke, chronic obstructive pulmonary disease (COPD), pulmonary circulation disorders, dementia, rheumatoid disease, peptic ulcer disease, liver disease, paralysis, other neurological disorders, chronic renal disease, cancer with/without metastasis, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), hypothyroidism, coagulopathy, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, psychosis, and depression [16,17]. The detailed description of diseases included as comorbidities with their respective ICD-10 codes is provided in Appendix A. In addition to individual comorbidities, the Charlson Comorbidity Index (CCI) was calculated using the ‘comorbidity’ package to measure the cumulative impact of comorbidities (except diabetes) on outcomes.

2.3. Ethical Considerations

The study was reviewed by the ethics committee of the Medical University of Graz, Graz, Austria (EK 32-355 ex 19/20) and conformed to the 1964 declaration of Helsinki and guidelines of the International Conference on Harmonization for Good Clinical Practice.
2.4. Statistical Analysis

Data were received in the Microsoft Excel format and analyzed in R version 4.1.0. Qualitative variables were summarized as frequencies with corresponding percentages (%) and compared with diabetes status using Pearson’s chi-square or Fischer’s exact tests and standardized mean differences (SMD).

The impact of diabetes on both ICU admission and in-hospital mortality was assessed using unmatched and PSM logistic regression. In unmatched logistic regression, the unadjusted association of diabetes with both outcomes was ascertained in the entire cohort (N = 40,602). In PSM analysis, the logistic regression model of diabetes with unbalanced variables having an SMD of $\geq 0.1$ each (Table 1) was fitted to estimate the propensity score. Next, the ‘MatchIt’ package was used to generate a 1:1 without replacement PSM cohort of diabetes (n = 4971) and non-diabetes (n = 4971) patients by applying the nearest neighbor method. After propensity score matching, the SMD was re-estimated in the PSM cohort to determine whether the balance was achieved across selected variables or not. The results of both unmatched and PSM logistic regression were reported as odds ratios (OR) with corresponding 95% confidence intervals (CI) and p-values. Furthermore, the association of diabetes with outcomes was adjusted for variables that remained unbalanced even after performing the PSM. A p-value of $<0.05$ was chosen to determine statistical significance.

**Table 1.** Characteristics and comorbidities of diabetes and non-diabetes patients hospitalized for COVID-19 patients in unmatched and propensity score matched cohorts.

| Variables                  | Unmatched Cohort |                  | PSM Cohort |                  |
|----------------------------|------------------|------------------|------------|------------------|
|                            | All              | No Diabetes     | Diabetes   | SMD   | p-Value | No Diabetes | Diabetes   | SMD   |
| N                          | 40,602           | 35,631 (87.8)   | 4971 (12.2)| 0.117 | $<0.001$ | 4971 (50.0) | 4971 (50.0) | 0.008 |
| Men                        | 21,278           | 18,419 (51.7)   | 2859 (57.5)| 0.028 |          | 2839 (57.1) | 2859 (57.5) | 0.008 |
| Women                      | 19,324           | 17,212 (48.3)   | 2112 (42.5)| 0.008 |          | 2132 (42.9) | 2112 (42.5) | 0.008 |
| Age categories             |                  |                  |            |       |          |            |            |       |
| 20–29                      | 1057 (2.6)       | 1050 (2.9)       | 7 (0.1)    | 0.403 | $<0.001$ | 5 (0.1)    | 7 (0.1)    | 0.028 |
| 30–39                      | 1576 (3.9)       | 1536 (4.3)       | 40 (0.8)   |       |          | 44 (0.9)   | 40 (0.8)   | 0.055 |
| 40–49                      | 2479 (6.1)       | 2306 (6.5)       | 173 (3.5)  |       |          | 177 (3.6)  | 173 (3.5)  | 0.028 |
| 50–59                      | 5363 (13.2)      | 4751 (13.3)      | 612 (12.3) | 0.403 | $<0.001$ | 643 (12.9) | 612 (12.3) | 0.028 |
| 60–69                      | 6674 (16.4)      | 5743 (16.1)      | 931 (18.7) |       |          | 931 (18.7) | 931 (18.7) | 0.055 |
| 70–79                      | 9664 (23.8)      | 8133 (22.8)      | 1531 (30.8)| 0.080 | $<0.001$ | 1490 (30.0)| 1531 (30.8)| 0.029 |
| 80–89                      | 10,532 (25.9)    | 9144 (25.7)      | 1388 (27.9)|       |          | 1387 (27.9)| 1388 (27.9)| 0.053 |
| 90+                        | 3257 (8.0)       | 2968 (8.3)       | 289 (5.8)  |       |          | 294 (5.9)  | 289 (5.8)  | 0.004 |
| ICU admission              | 5968 (14.7)      | 5057 (14.2)      | 911 (18.3) | 0.110 | $<0.001$ | 812 (16.3) | 911 (18.3) | 0.029 |
| In-hospital mortality      | 6569 (16.2)      | 5632 (15.8)      | 937 (18.8) | 0.080 | $<0.001$ | 881 (17.7) | 937 (18.8) | 0.055 |
| Comorbidities              |                  |                  |            |       |          |            |            |       |
| Myocardial infarction      | 340 (0.8)        | 236 (0.7)        | 104 (2.1)  | 0.123 | $<0.001$ | 107 (2.2)  | 104 (2.1)  | 0.004 |
| Cardiac arrhythmias        | 4235 (10.4)      | 3134 (8.8)       | 1101 (22.1)| 0.376 | $<0.001$ | 1217 (24.5)| 1101 (22.1)| 0.055 |
| Valvular heart disease     | 990 (2.4)        | 738 (2.1)        | 252 (5.1)  | 0.162 | $<0.001$ | 307 (6.2)  | 252 (5.1)  | 0.048 |
| Hypertension               | 10,538 (26.0)    | 7209 (20.2)      | 3329 (67.0)| 1.069 | $<0.001$ | 3002 (60.4)| 3329 (67.0)| 0.137 |
Table 1. Cont.

| Variables                        | All         | No Diabetes n (%) | Diabetes n (%) | SMD    | p-Value | No Diabetes n (%) | Diabetes n (%) | SMD    |
|----------------------------------|-------------|-------------------|----------------|--------|---------|-------------------|----------------|--------|
| Unmatched Cohort PSM Cohort      |             |                   |                |        |         |                   |                |        |
| CHF 2011 (5.0)                  | 1381 (3.9)  | 630 (12.7)        | 0.323          | <0.001 | 602 (12.1)| 630 (12.7)        | 0.017           |        |
| PVD 1341 (3.3)                  | 855 (2.4)   | 486 (9.8)         | 0.312          | <0.001 | 385 (7.7) | 486 (9.8)         | 0.072           |        |
| Stroke 1212 (3.0)               | 834 (2.3)   | 378 (7.6)         | 0.244          | <0.001 | 378 (7.6) | 378 (7.6)         | 0.002           |        |
| COPD 2271 (5.6)                 | 1699 (4.8)  | 572 (11.5)        | 0.248          | <0.001 | 568 (11.4)| 572 (11.5)        | 0.003           |        |
| Pulmonary circulation disorders  |             |                   |                |        |         |                   |                |        |
| Dementia 2050 (5.0)             | 1570 (4.4)  | 480 (9.7)         | 0.206          | <0.001 | 488 (9.8) | 480 (9.7)         | 0.005           |        |
| Rheumatoid disease              | 254 (0.6)   | 56 (1.1)          | 0.063          | <0.001 | 77 (1.5) | 56 (1.1)          | 0.037           |        |
| Peptic ulcer disease            | 86 (0.2)    | 24 (0.5)          | 0.054          | <0.001 | 20 (0.4) | 24 (0.5)          | 0.012           |        |
| Liver disease                   | 1031 (2.5)  | 359 (7.2)         | 0.258          | <0.001 | 305 (6.1) | 359 (7.2)         | 0.044           |        |
| Paralysis                       | 126 (0.3)   | 28 (0.6)          | 0.045          | 0.001  | 34 (0.7) | 28 (0.6)          | 0.015           |        |
| Other neurological disorders     | 1071 (2.6)  | 232 (4.7)         | 0.126          | <0.001 | 201 (4.0) | 232 (4.7)         | 0.031           |        |
| Renal disease                   | 3173 (7.8)  | 1081 (21.7)       | 0.473          | <0.001 | 1051 (21.1)| 1081 (21.7)       | 0.015           |        |
| Cancer                          | 1318 (3.2)  | 239 (4.8)         | 0.092          | <0.001 | 229 (4.6) | 239 (4.8)         | 0.009           |        |
| Hypothyroidism                  | 1335 (3.3)  | 342 (6.9)         | 0.192          | <0.001 | 347 (7.0) | 342 (6.9)         | 0.004           |        |
| Coagulation disorders           | 252 (0.6)   | 73 (1.5)          | 0.098          | <0.001 | 46 (0.9)  | 73 (1.5)          | 0.050           |        |
| Fluid and electrolyte disorders | 1433 (3.5)  | 302 (6.1)         | 0.138          | 0.001  | 307 (6.2) | 302 (6.1)         | 0.004           |        |
| Blood loss anaemia              | 37 (0.1)    | 9 (0.2)           | 0.028          | 0.046  | 8 (0.2)  | 9 (0.2)           | 0.005           |        |
| Deficiency anaemia              | 371 (0.9)   | 112 (2.3)         | 0.126          | <0.001 | 71 (1.4)  | 112 (2.3)         | 0.061           |        |
| Alcohol abuse                   | 241 (0.6)   | 51 (1.0)          | 0.056          | <0.001 | 77 (1.5)  | 51 (1.0)          | 0.046           |        |
| Drug abuse                      | 69 (0.2)    | 15 (0.3)          | 0.032          | 0.026  | 21 (0.4)  | 15 (0.3)          | 0.020           |        |
| Psychosis                       | 151 (0.4)   | 39 (0.8)          | 0.064          | <0.001 | 30 (0.6)  | 39 (0.8)          | 0.022           |        |
| Depression                      | 1074 (2.6)  | 248 (5.0)         | 0.143          | <0.001 | 248 (5.0) | 248 (5.0)         | 0.001           |        |
| Charlson Comorbidity Index      |             |                   |                |        |         |                   |                |        |
| 0                               | 30,361 (74.8)| 28,101 (78.9)    | 2260 (45.5)    |        | 2306 (46.4)| 2260 (45.5)       |                |        |
| 1–2                             | 7484 (18.4) | 5703 (16.0)       | 1781 (35.8)    |        | 1802 (36.3)| 1781 (35.8)       |                |        |
| 3–4                             | 2186 (5.4)  | 1441 (4.0)        | 745 (15.0)     | 0.744  | <0.001  | 694 (14.0)        | 745 (15.0)      | 0.035  |
| 5+                              | 571 (1.4)   | 386 (1.1)         | 185 (3.7)      |        | 169 (3.4) | 185 (3.7)         |                |        |

CHF: congestive heart failure, PVD: peripheral vascular disease, COPD: chronic obstructive pulmonary disease, PSM: propensity score matched, SMD: standardized mean difference. Pearson’s chi-square or Fisher’s exact tests were applied to compare diabetes with variables.

3. Results

Table 1 shows the distribution of characteristics and comorbidities of hospitalized COVID-19 patients in unmatched and PSM cohorts. In the unmatched cohort, two-thirds of patients were 60 to 89 years old and 52.4% were men. Common comorbidities were cardiovascular disease (33.1%), hypertension (26%), chronic renal disease (7.8%), COPD (5.6%), and dementia (5.0%). Of the total patients, 18.4% had a CCI score of 1–2, 5.4% had 3–4, and 1.4% had a score of ≥5.

A total of 4971 (12.2%) hospitalized patients had diabetes, 5968 (14.7%) were admitted to ICU, and 6569 (16.2%) died in the hospital. Patients with diabetes were older (p < 0.001), included more males (57.5% vs. 51.7%, p < 0.001), and had a higher ICU admission rate
(18.3% vs. 14.2%, \( p < 0.001 \)) and in-hospital mortality (18.8% vs. 15.8%, \( p < 0.001 \)) than those without diabetes. Among comorbidities, CVD (78.1% vs. 26.9%, \( p < 0.001 \)), COPD (11.5% vs. 4.8%, \( p < 0.001 \)), dementia (9.7% vs. 4.4%, \( p < 0.001 \)), liver disease (7.2% vs. 1.9%, \( p < 0.001 \)), chronic renal disease (21.7% vs. 5.9%, \( p < 0.001 \)), cancer (4.8% vs. 3.0%, \( p < 0.001 \)), hypothyroidism (6.9% vs. 2.8%, \( p < 0.001 \)), fluid and electrolyte disorders (6.1% vs. 3.2%, \( p < 0.001 \)), and depression (5.0% vs. 2.3%, \( p < 0.001 \)) were significantly more prevalent in patients with diabetes than those without diabetes. Patients with diabetes had significantly higher (\( p < 0.001 \)) CCI scores compared to patients without diabetes. In the PSM cohort of 4971 patients with diabetes and 4971 matched patients without diabetes, characteristics and comorbidities were well balanced for 13 variables as indicated by the SMD of <0.10 (Table 1).

Table 2 shows the comparison and logistic regression analysis of ICU admission with diabetes and other variables for both unmatched and PSM cohorts. In the unmatched analysis, patients with diabetes were 36% more likely (OR: 1.36, 95%CI: 1.25–1.47, \( p < 0.001 \)) to be admitted to ICU compared to patients without diabetes. This association was attenuated by more than half (OR: 1.15, 95%CI: 1.04–1.28, \( p = 0.009 \)) in the PSM analysis, nonetheless remaining significant. In addition, males and older patients were more likely to be admitted to ICU in both unmatched and PSM analyses. The odds of ICU admission were significantly higher in patients having a myocardial infarction, CHF, respiratory disorders, and coagulation disorders compared to those without these comorbidities in both unmatched and PSM analyses. A CCI score of 3–4 showed a significant association with ICU admission in the PSM analysis.

Table 3 shows the comparison and logistic regression analysis of in-hospital mortality with diabetes and other variables for both unmatched and PSM cohorts. The unmatched analysis showed 24% higher odds of mortality (OR: 1.24, 95%CI: 1.15–1.34, \( p < 0.001 \)) in people with diabetes compared to those without diabetes. The association of diabetes with in-hospital mortality (OR: 1.08, 95%CI: 0.97–1.19, \( p = 0.146 \)) became insignificant in the PSM analysis. Although hypertension was not well balanced between diabetes and non-diabetes patients, adjusting for it did not change the magnitude of association between diabetes and in-hospital mortality significantly (OR: 1.09, 95%CI: 0.99–1.21, \( p = 0.065 \)). In both unmatched and PSM analysis, the odds of mortality increased with age and CCI score and were significantly higher in males and those admitted to ICU. Patients with myocardial infarction, cardiac arrhythmias, valvular heart disease, congestive heart failure, peripheral artery disease, or stroke had higher odds of mortality (\( p < 0.001 \)) compared to those without these CVDs. Likewise, patients with COPD, pulmonary circulation disorders, dementia, chronic renal disease, cancer, and hypothyroidism had higher odds of mortality than those without these comorbidities.

Table 2. Comparison and simple logistic regression analysis of ICU admission with diabetes and other variables in unmatched and propensity score matched cohorts.

| Variables | Unmatched Cohort | PSM Cohort |
|-----------|-----------------|------------|
| Diabetes  |                 |            |
| No ICU Admission (N = 34,634) | n (%) | OR (95%CI) | p-Value | n (%) | OR (95%CI) | p-Value |
| ICU Admission (N = 5968) | n (%) | |
| N (%) | |
| Men | 4060 (11.7) | 111 (15.3) | 1.36 (1.25–1.47) | <0.001 | 115 (1.04–1.28) | 0.009 |
| Women | 17,430 (50.3) | 3848 (64.5) | Reference | Reference |
| Age groups | 17,204 (49.7) | 2120 (35.5) | 0.56 (0.53–0.59) | <0.001 | 0.56 (0.50–0.63) | <0.001 |
| 20–29 | 982 (2.8) | 75 (1.3) | Reference | Reference |
| 20–29 | 1427 (4.1) | 149 (2.5) | 1.37 (1.03–1.83) | 0.033 | 0.33 (0.09–1.47) | 0.138 |
| 30–39 | 2161 (6.2) | 318 (5.3) | 1.92 (1.49–2.52) | <0.001 | 0.60 (0.18–2.39) | 0.441 |
| 40–49 | 4556 (12.9) | 907 (15.2) | 2.66 (2.10–3.43) | <0.001 | 0.54 (0.17–2.11) | 0.348 |
| 50–59 | 5261 (15.2) | 1413 (23.7) | 3.51 (2.77–4.51) | <0.001 | 0.65 (0.20–2.54) | 0.507 |
| 60–69 | 7838 (22.6) | 1826 (30.6) | 3.04 (2.41–3.90) | <0.001 | 0.48 (0.15–1.89) | 0.271 |
Table 2. Cont.

| Variables                      | Unmatched Cohort | PSM Cohort |
|--------------------------------|------------------|------------|
|                                | No ICU Admission | ICU Admission |
|                                | (N = 34,634) n (%) | (N = 5968) n (%) | OR (95%CI) | p-Value | OR (95%CI) | p-Value |
| 80–89                          | 9365 (27.0)       | 1167 (19.6) | 1.63 (1.29–2.09) | <0.001 | 0.22 (0.07–0.86) | 0.032 |
| 90+                            | 3144 (9.1)        | 113 (1.9)   | 0.47 (0.35–0.64) | <0.001 | 0.04 (0.01–0.17) | <0.001 |
| Comorbidities                  |                  |            |                |        |                |        |
| Myocardial infarction          | 239 (0.7)         | 101 (1.7)   | 2.48 (1.95–3.12) | <0.001 | 2.27 (1.68–3.04) | <0.001 |
| Cardiac arrhythmias            | 3612 (10.4)       | 623 (10.4)  | 1.00 (0.91–1.09) | 0.978  | 0.93 (0.82–1.05) | 0.267  |
| Valvular heart diseases        | 844 (2.4)         | 146 (2.5)   | 1.00 (0.84–1.20) | 0.957  | 0.87 (0.69–1.10) | 0.255  |
| Hypertension                   | 8929 (25.8)       | 1609 (27.0) | 1.06 (1.00–1.13) | 0.056  | 1.09 (0.98–1.22) | 0.112  |
| Congestive heart failure       | 1676 (4.8)        | 335 (5.6)   | 1.17 (1.04–1.32) | 0.012  | 1.25 (1.08–1.45) | 0.004  |
| Peripheral vascular disease    | 1119 (3.2)        | 222 (3.7)   | 1.16 (1.00–1.34) | 0.054  | 1.07 (0.89–1.28) | 0.449  |
| Stroke                         | 1024 (3.0)        | 188 (3.1)   | 1.07 (0.91–1.25) | 0.416  | 1.01 (0.83–1.22) | 0.915  |
| COPD                           | 1854 (5.3)        | 417 (7.0)   | 1.33 (1.19–1.48) | <0.001 | 1.23 (1.05–1.43) | 0.010  |
| Pulmonary circulation disorders| 436 (1.3)         | 155 (2.6)   | 2.09 (1.73–2.51) | <0.001 | 2.19 (1.65–2.87) | <0.001 |
| Dementia                       | 1975 (5.7)        | 75 (1.3)    | 0.21 (0.17–0.26) | <0.001 | 0.14 (0.09–0.20) | <0.001 |
| Rheumatoid disorders           | 227 (0.7)         | 27 (0.5)    | 0.69 (0.45–1.01) | 0.059  | 0.65 (0.37–1.07) | 0.097  |
| Peptic ulcer disease           | 68 (0.2)          | 18 (0.3)    | 1.55 (0.89–2.55) | 0.116  | 1.08 (0.46–2.21) | 0.852  |
| Liver disease                  | 848 (2.5)         | 183 (3.1)   | 1.26 (1.07–1.48) | 0.006  | 1.15 (0.94–1.40) | 0.173  |
| Paralysis                      | 105 (0.3)         | 21 (0.3)    | 1.17 (0.71–1.83) | 0.524  | 1.68 (0.92–2.91) | 0.091  |
| Other neurological disorders   | 970 (2.8)         | 101 (1.7)   | 0.60 (0.48–0.73) | <0.001 | 0.56 (0.40–0.75) | <0.001 |
| Renal disease                  | 2741 (7.9)        | 432 (7.2)   | 0.91 (0.82–1.01) | 0.071  | 0.81 (0.71–0.93) | 0.002  |
| Cancer                         | 1128 (3.3)        | 190 (3.2)   | 0.98 (0.83–1.14) | 0.774  | 1.00 (0.78–1.27) | 0.999  |
| Hypothyroidism                 | 1157 (3.3)        | 178 (3.0)   | 0.89 (0.76–1.04) | 0.150  | 0.93 (0.75–1.14) | 0.508  |
| Coagulation disorders          | 167 (0.5)         | 85 (1.4)    | 2.98 (2.29–3.87) | <0.001 | 4.06 (2.81–5.85) | <0.001 |
| Fluid and electrolyte disorders| 1280 (3.7)        | 153 (2.6)   | 0.69 (0.58–0.81) | <0.001 | 0.89 (0.71–1.11) | 0.292  |
| Deficiency anemia              | 328 (0.9)         | 43 (0.7)    | 0.76 (0.55–1.04) | 0.084  | 0.72 (0.46–1.09) | 0.123  |
| Alcohol abuse                  | 188 (0.5)         | 53 (0.9)    | 1.65 (1.20–2.22) | 0.002  | 1.54 (1.01–2.29) | 0.046  |
| Psychosis                      | 126 (0.4)         | 25 (0.4)    | 1.16 (0.74–1.75) | 0.511  | 1.12 (0.58–1.99) | 0.721  |
| Depression                     | 937 (2.7)         | 137 (2.3)   | 0.85 (0.70–1.01) | 0.065  | 0.93 (0.72–1.18) | 0.552  |
| Charlson Comorbidity Index     |                  |            |                |        |                |        |
| 0                              | 25,868 (74.7)     | 4493 (75.3) | Reference      | Reference |
| 1–2                            | 6383 (18.4)       | 1101 (18.4) | 0.99 (0.92–1.07) | 0.851  | 0.90 (0.80–1.01) | 0.083  |
| 3–4                            | 1885 (5.4)        | 301 (5.0)   | 0.92 (0.81–1.04) | 0.188  | 0.84 (0.72–0.99) | 0.035  |
| 5+                             | 498 (1.4)         | 73 (1.2)    | 0.85 (0.65–1.08) | 0.176  | 0.79 (0.58–1.05) | 0.110  |

CI: confidence interval, COPD: chronic obstructive pulmonary disease, ICU: intensive care unit, OR: odds ratio, PSM: propensity score matched.

Table 3. Comparison and simple logistic regression analysis of in-hospital mortality with diabetes and other variables in unmatched and propensity score-matched cohorts.

| Variables                      | Unmatched Cohort | PSM Cohort |
|--------------------------------|------------------|------------|
|                                | No In-Hospital Mortality (N = 34,033) n (%) | In-Hospital Mortality (N = 6569) n (%) | OR (95%CI) | p-Value | OR (95%CI) | p-Value |
| Diabetes                       | 4034 (11.9)      | 937 (14.3) | 1.24 (1.15–1.34) | <0.001 | 1.08 (0.97–1.19) | 0.146 |
| Men                            | 17,582 (51.7)    | 3696 (56.3) | Reference | Reference |
| Women                          | 16,451 (48.3)    | 2873 (43.7) | 0.83 (0.79–0.88) | <0.001 | 0.84 (0.76–0.94) | <0.001 |
Table 3. Cont.

| Variables                      | Unmatched Cohort | PSM Cohort |
|--------------------------------|------------------|------------|
|                                | In-Hospital Mortality (N = 34,033) n (%) | OR (95%CI) p-Value | In-Hospital Mortality (N = 6569) n (%) | OR (95%CI) p-Value |
| Age                            |                  |            |
| 20–29                          | 1048 (3.1)       | Reference | 190 (2.9)                   | 4.20 (2.28–8.92) <0.001 |
| 30–39                          | 1557 (4.6)       | 1.41 (0.65–3.31) 0.396 | 35 (0.5)                   | 1.65 (0.82–3.68) 0.168 |
| 40–49                          | 2444 (7.2)       | 0.14 (0.00–5.63) 0.250 | Reference                  | Reference |
| 50–59                          | 5173 (15.2)      | 0.12 (0.01–3.42) 0.165 | 190 (2.9)                   | 4.20 (2.28–8.92) <0.001 |
| 60–69                          | 6093 (17.9)      | 0.46 (0.09–11.60) 0.533 | 581 (8.8)                   | 10.90 (5.99–22.90) <0.001 |
| 70–79                          | 8018 (23.6)      | 2.35 (1.29–4.92) 0.022 | 1646 (25.1)                 | 23.50 (12.9–49.20) <0.001 |
| 80–89                          | 7727 (22.7)      | 3.75 (0.72–18.20) 0.133 | 2805 (42.7)                 | 41.50 (22.9–87.00) <0.001 |
| 90+                            | 1973 (5.8)       | 6.80 (1.02–41.80) 0.001 | 1284 (19.5)                 | 74.40 (40.9–157.00) <0.001 |
| ICU admission                  | 3991 (11.7)      | 3.24 (3.04–3.45) <0.001 | 1977 (30.1)                 | 3.24 (3.04–3.45) <0.001 |
| Comorbidities                  |                  |            |
| Myocardial infarction          | 219 (0.6)        | 2.90 (2.31–3.62) <0.001 | 121 (1.8)                   | 2.90 (2.31–3.62) <0.001 |
| Cardiac arrhythmias            | 3160 (9.3)       | 1.91 (1.77–2.06) <0.001 | 1075 (16.4)                 | 1.91 (1.77–2.06) <0.001 |
| Valvular heart disease         | 751 (2.2)        | 1.67 (1.44–1.94) <0.001 | 239 (3.6)                   | 1.67 (1.44–1.94) <0.001 |
| Hypertension                   | 8737 (25.7)      | 1.09 (1.03–1.16) 0.003 | 1801 (27.4)                 | 1.09 (1.03–1.16) 0.003 |
| Congestive heart failure       | 1326 (3.9)       | 2.87 (2.61–3.16) <0.001 | 685 (10.4)                  | 2.87 (2.61–3.16) <0.001 |
| Peripheral vascular disease    | 962 (2.8)        | 2.11 (1.86–2.38) <0.001 | 379 (5.8)                   | 2.11 (1.86–2.38) <0.001 |
| Stroke                         | 887 (2.6)        | 1.95 (1.71–2.21) <0.001 | 325 (4.9)                   | 1.95 (1.71–2.21) <0.001 |
| COPD                           | 1815 (5.3)       | 1.32 (1.19–1.47) <0.001 | 456 (6.9)                   | 1.32 (1.19–1.47) <0.001 |
| Pulmonary circulation disorders| 457 (1.3)        | 1.53 (1.26–1.85) <0.001 | 134 (2.0)                   | 1.53 (1.26–1.85) <0.001 |
| Dementia                       | 1344 (3.9)       | 2.93 (2.66–3.22) <0.001 | 706 (10.7)                  | 2.93 (2.66–3.22) <0.001 |
| Rheumatoid disease             | 205 (0.6)        | 1.24 (0.90–1.68) 0.183 | 49 (0.7)                    | 1.24 (0.90–1.68) 0.183 |
| Peptic ulcer disease           | 66 (0.2)         | 1.58 (0.93–2.56) 0.087 | 20 (0.3)                    | 1.58 (0.93–2.56) 0.087 |
| Liver disease                  | 847 (2.5)        | 1.13 (0.96–1.32) 0.144 | 184 (2.8)                   | 1.13 (0.96–1.32) 0.144 |
| Paralysis                      | 100 (0.3)        | 1.35 (0.86–2.06) 0.183 | 26 (0.4)                    | 1.35 (0.86–2.06) 0.183 |
| Other neurological disorders   | 774 (2.3)        | 2.04 (1.77–2.33) <0.001 | 297 (4.5)                   | 2.04 (1.77–2.33) <0.001 |
| Renal disease                  | 2243 (6.6)       | 2.34 (2.15–2.54) <0.001 | 930 (14.2)                  | 2.34 (2.15–2.54) <0.001 |
| Cancer                         | 965 (2.8)        | 1.95 (1.72–2.20) <0.001 | 353 (5.4)                   | 1.95 (1.72–2.20) <0.001 |
| Hypothyroidism                 | 1171 (3.4)       | 0.72 (0.61–0.85) 0.001 | 164 (2.5)                   | 0.72 (0.61–0.85) 0.001 |
| Coagulation disorders          | 193 (0.6)        | 1.59 (1.18–2.12) 0.003 | 59 (0.9)                    | 1.59 (1.18–2.12) 0.003 |
| Fluid and electrolyte disorders| 1172 (3.4)       | 1.16 (1.01–1.33) 0.036 | 261 (4.0)                   | 1.16 (1.01–1.33) 0.036 |
| Deficiency anaemia             | 307 (0.9)        | 1.08 (0.82–1.41) 0.567 | 64 (1.0)                    | 1.08 (0.82–1.41) 0.567 |
| Alcohol abuse                  | 177 (0.5)        | 1.88 (1.40–2.50) <0.001 | 64 (1.0)                    | 1.88 (1.40–2.50) <0.001 |
| Psychosis                      | 125 (0.4)        | 1.08 (0.69–1.63) 0.714 | 26 (0.4)                    | 1.08 (0.69–1.63) 0.714 |
| Depression                     | 907 (2.7)        | 0.95 (0.80–1.12) 0.575 | 167 (2.5)                   | 0.95 (0.80–1.12) 0.575 |
| Charlson Comorbidity Index     |                  |            |
| 0                              | 26,400 (77.6)    | Reference | 3961 (60.3)                  | Reference |
| 1–2                            | 5752 (16.9)      | 2.01 (1.88–2.14) <0.001 | 1732 (26.4)                 | 2.01 (1.88–2.14) <0.001 |
| 3–4                            | 1491 (4.4)       | 3.11 (2.82–3.42) <0.001 | 695 (10.6)                  | 3.11 (2.82–3.42) <0.001 |
| 5+                             | 390 (1.1)        | 3.09 (2.58–3.70) <0.001 | 181 (2.76)                  | 3.09 (2.58–3.70) <0.001 |

CI: confidence interval, COPD: chronic obstructive pulmonary disease, OR: odds ratio, PSM: propensity score matched.
4. Discussion

This countrywide retrospective study examined the impact of diabetes on the severity of the infection and in-hospital mortality in patients hospitalized for COVID-19. The analysis showed that hospitalized COVID-19 patients with diabetes were older and had a higher burden of multimorbidity and CCI score compared to those without diabetes. Patients with diabetes were more likely to have severe COVID-19 disease than those without diabetes as evidenced by higher odds of ICU admission even after propensity matching of characteristics, comorbidities, and the CCI score. However, diabetes was not independently associated with in-hospital mortality after matching diabetes and non-diabetes cohorts. While old age, male sex, and comorbidities were significantly associated with both outcomes in unmatched and matched analyses.

This study adopted the PSM method to assess the independent impact of diabetes on the severity of COVID-19 and in-hospital mortality. The association of diabetes with mortality was attenuated threefold i.e., from 24% in the unmatched cohort to 8% in the PSM cohort. These findings suggest that diabetes has no independent impact on in-hospital mortality in COVID-19 patients. Instead, advanced age, sex, and multimorbidity are responsible for the previously shown association between diabetes and in-hospital mortality. Our findings are consistent with a previous study that employed the PSM analysis and found no significant association between diabetes and in-hospital mortality in French patients hospitalized for COVID-19 [14]. In contrast, most studies have reported a significant positive association between diabetes and COVID-19 related mortality. For instance, a recent meta-analysis has demonstrated a significant association between diabetes and COVID-19 mortality that attenuated after adjusting for age and comorbidities [18]. Another meta-analysis of 31,067 patients has also reported a higher COVID-19 related mortality in patients with diabetes [19]. Similarly, a large study in England reported 80% higher odds of COVID-19 deaths in people with type 2 diabetes than those without diabetes [20]. Likewise, two small studies from China found diabetes to be a significant risk factor of mortality in COVID-19 patients even after adjusting for comorbidities and laboratory markers [21,22]. Even though previous studies have demonstrated a significant association between diabetes and COVID-19 mortality, most studies and those included in meta-analyses have not adjusted for various significant comorbidities and risk factors. These limitations further support our finding regarding the underlying impact of age, sex, and multimorbidity on COVID-19 mortality in patients with diabetes.

In this study, patients with diabetes were 36% more likely to have severe COVID-19 disease as represented by ICU admission in the unmatched analysis that decreased to 15% in the PSM analysis but remained significant. These findings are consistent with previous studies; however, the direct comparison across studies is not possible because of differences in defining criteria of the severity of COVID-19 disease and statistical analysis methods across studies. Moreover, the degree of association between diabetes and the severity of COVID-19 disease in our study is much lower than in other studies. For instance, meta-analyses performed in different phases of the COVID-19 pandemic have reported the pooled odds of developing severe COVID-19 disease ranging from 1.58 to 2.75 in people with diabetes compared to non-diabetes [23–26]. The vast heterogeneity in the degree of association between diabetes and COVID-19 severity is primarily due to different adjustment factors like age, obesity, smoking, and comorbidities considered by studies [24,27]. Moreover, previous studies have shown that glucose-lowering medication might be associated with COVID-19 outcomes [28]. However, we could not adjust for medication in our study due to the unavailability of treatment regimen information. Of note, dementia was associated with in-hospital mortality, while it was significantly associated with lower ICU admission. We believe that this association is rather due to a selection bias of patients being admitted to ICU than a biological association.

Our findings must be interpreted with some limitations. As common in healthcare data, there is a possibility of miscoding or under-coding of diagnoses in this database. Therefore, diabetes was not classified into subtypes because of the uncertainty in the ICD
coding accuracy of this diagnosis. Moreover, laboratory measurements of glucose and other biochemical parameters were not available for all patients and therefore not included in the analysis. This limitation might have resulted in residual confounding between diabetes and COVID-19 outcomes. Furthermore, in-hospital mortality was defined as death from any underlying cause, which might have captured deaths resulting from causes other than COVID-19. However, considering that this database holds data only on patients with COVID-19, the likelihood of including non-COVID-19-related deaths is low. In addition, we only analyzed in-hospital mortality in this study, however previous studies have shown that the pandemic might impact overall mortality in people with diabetes as well [29]. Last, our cohort comprised Austrian citizens only, hence the findings might not be generalized to other populations with different ethnicities.

5. Conclusions

This countrywide retrospective cohort analysis of patients hospitalized for COVID-19 found that people with diabetes had an advanced age and a higher burden of multimorbidity compared to those without diabetes. Consistent with the existing research, hospitalized patients with diabetes were significantly more likely to suffer from severe COVID-19 illness compared to those without diabetes; whereas, comorbidities and old age rather than diabetes per se were responsible for the increased likelihood of COVID-19 related in-hospital mortality. This study has confirmed that advanced age and comorbidities play a major role in both COVID-19 disease severity and death even in patients with diabetes and hence should be considered in risk stratification, management of patients, and national vaccination strategies.

Author Contributions: Conceptualization, F.A. (Faisal Aziz), H.S. (Harald Sourij) and S.K.; methodology, F.A. (Faisal Aziz), H.S. (Harald Sourij) and S.K.; software, F.A. (Faisal Aziz); validation, H.S. (Harald Sourij) and S.K.; formal analysis, F.A. (Faisal Aziz); investigation, H.S. (Harald Sourij); resources, H.S. (Harald Sourij); data curation, F.A. (Faisal Aziz); writing—original draft preparation, F.A. (Faisal Aziz), H.S. (Harald Sourij), S.K., F.A. (Felix Aberer), and N.T.; writing—review and editing, All co-authors; visualization, F.A. (Faisal Aziz) and H.S. (Harald Sourij); supervision, H.S. (Harald Sourij) and S.K. All authors have read and agreed to the published version of the manuscript.

Funding: This study did not receive any funding.

Institutional Review Board Statement: The study was reviewed by the ethics committee of the Medical University of Graz, Graz, Austria (EK 32-355 ex 19/20) and conformed to the 1964 declaration of Helsinki and guidelines of the International Conference on Harmonization for Good Clinical Practice (ICH GCP E6 guidelines).

Informed Consent Statement: This study was a retrospective analysis of anonymized data, therefore, no informed consent was obtained from the patients.

Data Availability Statement: Data included in this study is a property of the Austrian National Public Health Institute (Gesundheit Österreich GmbH). Further information regarding data access is available at: https://datenplattform-covid.goeg.at/english, accessed on 3 May 2021.

Acknowledgments: F.A. (Faisal Aziz) and H.S. (Harald Sourij) are guarantors of the work.

Conflicts of Interest: All authors do not have any conflict of interest to declare.
## Appendix A

### Table A1. ICD-10 codes of comorbidities.

| Comorbidities                                      | ICD-10 Codes                  |
|---------------------------------------------------|-------------------------------|
| Hypertension                                      | I10.x, I11.x–I13.x, I15.x    |
| Myocardial infarction/Ischaemic heart disease     | I21.x, I22.x, I25.x           |
| Congestive heart failure                          | I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0 |
| Cardiac arrhythmias                               | I44.1–I44.3, I45.6, I45.9, I47.x–I49.x, R00.0, R00.1, R00.8, T82.1, Z45.0, Z95.0 |
| Valvular disease                                  | A52.0, I05.x–I08.x, I09.1, I09.8, I34.x–I39.x, Q23.0–Q23.3, Z95.2–Z95.4 |
| Peripheral vascular disease                       | I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9 |
| Cerebrovascular disease                           | G45.x, G46.x, H34.0, I60.x–I69.x |
| Dementia                                          | F00.x–F03.x, F05.1, G30.x, G31.1 |
| Chronic obstructive pulmonary disease             | I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, J70.3 |
| Pulmonary circulation disorders                   | I26.x, I27.x, I28.0, I28.8, I28.9 |
| Rheumatic disease                                 | M05.x, M06.x, M31.5, M32.x–M34.x, M35.1, M35.3, M36.0 |
| Peptic ulcer disease                              | K25.x–K28.x |
| Liver disease                                     | B18.x, K70.0–K70.3, K70.9, K71.3–K71.5, K71.7, K73.x, K74.x, K76.0, K76.2–K76.4, K76.8, K76.9, Z94.4, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5, K76.6, K76.7 |
| Diabetes                                           | E10.x, E11.x, E12.x, E13.x, E14.x |
| Paralysis                                          | G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0–G83.4, G83.9 |
| Other neurological disorders                      | G10.x–G13.x, G20.x–G22.x, G25.4, G25.5, G31.2, G31.8, G31.9, G32.x, G35.x–G37.x, G40.x, G41.x, G93.1, G93.4, R47.0, R56.x |
| Hypothyroidism                                     | E00.x–E03.x, E89.0 |
| Renal disease                                      | I12.0, I13.1, N03.2–N03.7, N05.2–N05.7, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2 |
| Any malignancy, except malignant neoplasm of skin | C00.x – C26.x, C30.x – C34.x, C37.x – C41.x, C43.x, C45.x – C58.x, C60.x – C76.x, C81.x – C85.x, C88.x, C90.x – C97.x |
| Metastatic solid tumour                            | C77.x–C80.0 |
| AIDS/HIV                                           | B20.x–B22.x, B24.x |
| Rheumatoid arthritis/collagen vascular diseases   | L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, M12.3, M30.x, M31.0–M31.3, M32.x–M35.x, M45.x, M46.1, M46.8, M46.9 |
| Coagulopathy                                       | D65–D68.x, D69.1, D69.3–D69.6 |
| Fluid and electrolyte disorders                   | E22.2, E86.x, E87.x |
| Blood loss anaemia                                 | D50.0 |
| Deficiency anaemia                                 | D50.8, D50.9, D51.x–D53.x |
| Alcohol abuse                                      | F10, E52, G62.1, H42.6, K29.2, K70.0, K70.3, K70.9, T51.x, Z50.2, Z71.4, Z72.1 |
| Drug abuse                                         | F11.x–F16.x, F18.x, F19.x, Z71.5, Z72.2 |
| Psychoses                                          | F20.x, F22.x–F25.x, F28.x, F29.x, F30.2, F31.2, F31.5 |
| Depression                                         | F20.4, F31.3–F31.5, F32.x, F33.x, F34.1, F41.2, F43.2 |
References

1. WHO. Situation by Country, Territory & Area. Available online: https://covid19.who.int (accessed on 27 September 2021).
2. Ritchie, H.; Ortiz-Ospina, E.; Beltekian, D.; Mathieu, E.; Hasell, J.; Macdonald, B.; Giattino, C.; Appel, C.; Rodé-Suírao, L.; Roser, M. Coronavirus Pandemic (COVID-19). Available online: https://ourworldindata.org/mortality-risk-covid (accessed on 9 July 2021).
3. Grasselli, G.; Zangrillo, A.; Zanella, A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 323, 1574–1581. [CrossRef]
4. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395, 1054–1062. [CrossRef]
5. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W. Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA 2020, 323, 2052–2059. [CrossRef]
6. Shi, Q.; Zhang, X.; Jiang, F.; Zhang, X.; Hu, N.; Bimu, C.; Feng, J.; Yan, S.; Guan, Y.; Xu, D.; et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care 2020, 43, 1382–1391. [CrossRef] [PubMed]
7. Sanyalou, A.; Okorie, C.; Marinkovic, A.; Patidar, R.; Younis, K.; Desai, P.; Hosein, Z.; Padda, I.; Mangat, J.; Altmf, M. Comororbidity and its Impact on Patients with COVID-19. SN Compr. Clin. Med. 2020, 2, 1069–1076. [CrossRef]
8. Lim, S.; Bae, J.H.; Kwon, H.-S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021, 17, 11–30. [CrossRef] [PubMed]
9. Ejaz, H.; Alsharni, A.; Zafar, A.; Javed, H.; Junaid, K.; Abdalla, A.E.; Abosalif, K.O.; Ahmed, Z.; Younas, S. COVID-19 and comorbidities: Deleterious impact on infected patients. J. Infect. Public Health 2020, 13, 1833–1839. [CrossRef] [PubMed]
10. Cho, S.I.; Yoon, S.; Lee, H.-J. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. Sci. Rep. 2021, 11, 6375. [CrossRef]
11. Sourij, H.; Aziz, F.; Bräuer, A.; Ciardi, C.; Clodi, M.; Fasching, P.; Kauztky-Willer, A.; Klammer, C.; Malle, O.; et al. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes. Metab. 2021, 23, 589–598. [CrossRef] [PubMed]
12. Feldman, E.L.; Savelief, M.G.; Hayek, S.S.; Pennathur, S.; Kretzler, M.; Pop-Busui, R. COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes 2020, 69, 2549–2565. [CrossRef]
13. Heal, A.H.; Livingston, M.; Moreno, G.; Gibson, J.M. The risk factors potentially influencing risk of serious illness/death in people with diabetes, following SARS-CoV-2 infection: What needs to be done from here. Cardiovasc. Endocrinol. Metab. 2021, 10, 231–232. [CrossRef] [PubMed]
14. Sutter, W.; Duceau, B.; Vignac, M.; Bonnet, G.; Carlier, A.; Roussel, R.; Trimaille, A.; Pommier, T.; Guilleminot, P.; Sagnard, A.; et al. Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. Diabetes Metab. 2021, 47, 101222. [CrossRef] [PubMed]
15. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandebroucke, J.P.; Strobe Initiative. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [CrossRef]
16. Chan, H.; Li, B.; Couris, C.M.; Fushimi, K.; Graham, P.; Hider, P.; Januel, J.-M.; Sundararajan, V. Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries. Am. J. Epidemiol. 2011, 173, 676–682. [CrossRef] [PubMed]
17. Elixhauser, A.; Steiner, C.; Harris, D.R.; Coffey, R.M. Comorbidity Measures for Use with Administrative Data. Med. Care 1998, 36, 8–27. [CrossRef]
18. Corona, G.; Pizzocaro, A.; Vena, W.; Rastrelli, G.; Semeraro, F.; Isidori, A.M.; Pivonello, R.; Salonia, A.; Sforza, A.; Maggi, M. Diabetes is the most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 2021, 22, 275–296. [CrossRef]
19. Shang, L.; Shao, M.; Guo, Q.; Shi, J.; Zhao, Y.; Xiaokereti, J.; Tang, B. Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis. Arch. Med. Res. 2020, 51, 700–709. [CrossRef]
20. Barron, E.; Bakhai, C.; Kar, P.; Weaver, A.; Bradley, D.; Ismail, H.; Knighton, P.; Holman, N.; Khunti, K.; Sattar, N.; et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020, 8, 813–822. [CrossRef]
21. Zhang, Y.; Cui, Y.; Shen, M.; Zhang, J.; Liu, B.; Dai, M.; Chen, L.; Han, D.; Fan, Y.; Zeng, Y.; et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Res. Clin. Pract. 2020, 165, 108227. [CrossRef]
22. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metab. Res. Rev. 2020, 36, e3319. [CrossRef] [PubMed]
23. Kumar, A.; Arora, A.; Sharma, P.; Anikhindi, S.A.; Bansal, N.; Singla, V.; Khare, S.; Srivastava, A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 535–545. [CrossRef] [PubMed]
24. Li, X.; Zhong, X.; Wang, Y.; Zeng, X.; Luo, T.; Liu, Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLoS ONE* 2021, 16, e0250602. [CrossRef] [PubMed]

25. Liang, X.; Xu, J.; Xiao, W.; Shi, L.; Yang, H. The association of diabetes with COVID-19 disease severity: Evidence from adjusted effect estimates. *Hormones* 2021, 20, 409–414. [CrossRef]

26. Mantovani, A.; Byrne, C.D.; Zheng, M.-H.; Targher, G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr. Metab. Cardiovasc. Dis.* 2020, 30, 1236–1248. [CrossRef]

27. Gao, X.; Ke, C.; Liu, H.; Liu, W.; Li, K.; Yu, B.; Sun, M. Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis. *Sci. Rep.* 2017, 7, 11817. [CrossRef]

28. Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. *Diabetes Care* 2020, 43, 1399–1407. [CrossRef] [PubMed]

29. Ran, J.; Zhao, S.; Han, L.; Ge, Y.; Chong, M.K.; Cao, W.; Sun, S. Increase in Diabetes Mortality Associated With COVID-19 Pandemic in the US. *Diabetes Care* 2021, 44, e146–e147. [CrossRef]